Research programme: potassium channel modulators - Pharmexa/Poseidon

Drug Profile

Research programme: potassium channel modulators - Pharmexa/Poseidon

Latest Information Update: 27 Mar 2007

Price : $50

At a glance

  • Originator Pharmexa; Poseidon Pharmaceuticals
  • Class
  • Mechanism of Action Immunosuppressants; Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Transplant rejection; Urinary incontinence

Most Recent Events

  • 25 Nov 2003 This programme is still in active development
  • 22 Jun 2001 M&E Biotech is now called Pharmexa
  • 13 Sep 2000 NeuroSearch is collaborating with M&E Biotech on researching the immunosuppressive potential of the potassium channel modulators
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top